Posted by Michael Wonder on 13 Sep 2021
Reimagining pharmaceutical market exclusivities: should the duration of guaranteed monopoly periods be value based?
13 September 2021 - The amount of time in which brand pharmaceutical markets are protected does not correspond with the products’ potential health impact or price.
Beall and colleagues outline an alternative system that assigns the duration of exclusive market time protected by the regulatory authority as a function of a product’s value.
